Clinical Trials

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.

As CEO Reshma Kewalramani takes the stage, investors will look for clues on how Vertex plans to pivot from CF dominance to a multi-franchise powerhouse.

ADC Therapeutics' lymphoma drug ZYNLONTA shows promise in a Phase 3 trial, but a concerning safety signal in older patients complicates its path to market.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

As Prime Medicine prepares for a key investor conference, its next-gen 'search and replace' gene editing technology faces a crucial test. Can it deliver on its promise?

A parent-founded nonprofit is funding a landmark gene therapy trial, aiming to create the first-ever treatment for a rare neurodevelopmental disorder.

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

A pivotal partnership between WeInfuse and Trial IQ leverages AI to bring clinical trials to local infusion centers, signaling a major shift in drug development.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

A new partnership is democratizing science for wellness brands, making it faster and cheaper to prove their final products work and earn customer trust.

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

A new alliance between Solid Biosciences and NanoMosaic pairs advanced delivery with precision analytics, aiming to de-risk development and redefine success.